Galectin-3 and Natriuretic Peptides are distinct and complementary markers of chronic heart failure1,2
For many years natriuretic peptides, such as BNP and NT-proBNP testing, have aided in the diagnosis and evaluation of heart failure (HF). However, these tests may not provide full prognostic information when used alone. Galectin-3 provides independent and additive information to traditional BNP and NT-proBNP testing that may help identify more patients at higher risk of near term adverse events, including hospitalization and mortality.
||BNP / NT-proBNP
||Mediator of cardiac fibroblast proliferation
||Fibrogenesis and cardiac remodeling
|Role in HF
||Indicator of active cardiac fibrosis
(mediator of myofibroblast activation, interstitial fibrosis and adverse cardiac remodeling)
|Indicator of hemodynamic stress (marker of wall tension determined by chamber size and pressure)
|Clinical applications in HF
||Prognosis in chronic HF patients
||Diagnosis of HF
Risk stratification in HF
Assessment of HF severity
|Recognized in ACCF/AHA HF Management Guideline
1. BGM Galectin-3® Product Insert (US)
2. de Boer RA, et al. Annals of Med 2011; 43(1): 60-8
CPT® is a registered trademark of the American Medical Association.
For additional information consult the current Clinical Diagnostic Laboratory Fee Schedule.
The BGM Galectin-3® Test is an in vitro diagnostic device that quantitatively measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay (ELISA) on a microtiter plate platform, to be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. For full prescribing information, including warnings and precautions, please refer to the product insert.